MANAGEMENT DISCUSSION AND ANALYSIS


OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


For the THREE MONTHS ENDED February 28, 2023


The following...

Related Keywords

Toronto , Ontario , Canada , Malaysia , Apis , Northern Samar , Philippines , United States , China , Delaware , Vietnam , Republic Of , New York , Canadian , Vietnamese , America , Malaysian , Isa Odidi , Amina Odidi , Purdue Pharma , Christopher Pearce , Steven Boyd , Victor Romita , Anstalt Alpha , Program Fee , Intellipharmaceutics Ltd , A Company , Us District Court , Company Registration Statement On Form , Company Common , Scientific Research Experimental Development , Drug Products Advisory Committee , Hc Wainwright Co , Canadian Intellectual Property Office , Taro Pharmaceuticals Inc Canada , Us Securities Exchange , Vasogen Inc , Intellipharmaceutics Intl Inc , While The Company , Pf Laboratories Inc , Purdue Pharmaceuticals , Toronto Stock Exchange , Teva Pharmaceuticals United States Inc , Drug Administration , Party Transactions , Ontario Securities Commission , Tris Pharma Inc , Trademark Office , Wyeth Pharmaceuticals , Us Federal Circuit Court , Nasdaq Panel , Company Corporate Governance Committee , Nasdaq , Stage Of Development , Armistice Capital , Canadian Chartered Bank , Armistice Capital Master Fund Ltd , District Court , Company Aximris , Taro Pharmaceuticals Inc , Pfizer Inc , Intellipharmaceutics International Inc , Health Canada , Intellipharmaceutics Corp , Astrazeneca , United States District Court , Us Supreme Court , Foreign Exchange Gain Loss , Pfizer , Exchange Commission On , Sabby Volatility Warrant Master Fund Ltd , Management Discussion , Intellipharmaceutics International , Financial Accounting Standards Board , Accounting Standards Codification , Drug Delivery Engine , United States Food , Securities Act , Abbreviated New Drug Applications , New Drug Applications , National Policy , File Cease Trade Orders , Multiple Jurisdictions , Universal Market Integrity Rules , Investment Industry Regulatory Organization , Chief Executive Officer , Chief Financial Officer , Cease Trade , Taro Pharmaceuticals , Desvenlafaxine Extended Release Tablets , Pharmaceutical Drugs Directory , Par Pharmaceutical , United States Patent , Divergence Drug Delivery , Paradoxical Overdose Resistance Activating System , Abuse Deterrent Opioids , Fast Track , Canadian Patent , Pharmaceuticals Inc , Potential Products , Transferred Levetiracetam , Teva Pharmaceuticals United States , Tris Pharma , Prescription Drug User Fee Act , Deterrent Opioids , Hatch Waxman Act , Drug Products , Therapeutic Equivalence Evaluations , Orange Book , Rhodes Technologies , Circuit Court , Purdue Oxycontin , Litigations The , Advisory Committees , Complete Response Letter , Analgesic Drug Products Advisory Committee , Pregabalin Extended Release , Pre Investigational New Drug , Abuse Deterrent , Scientific Research , Experimental Development , Exchange Gain , Effective May , Nasdaq Listing Rule , Canadian Chartered , Southern District , Intl Inc , Exchange Act , Superior Court , Ontario Class Proceedings , Ontario Securities Act , Amended Motion Record , Amended Notice , Amended Statement , Alpha Capital Anstalt , Chief Financial , Registration Statement , Exchange Commission , Magistrate Judge , Motion Record , Armistice Capital Master Fund , Sabby Volatility Warrant Master Fund , Corporate Governance Committee , Control Integrated Framework , Sponsoring Organizations , Treadway Commission , Internal Control , Annual Information Form , Markets ,